Transcutaneous aortic valve implantation

Margaret A. Lloyd, Charanjit S. Rihal

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Non-rheumatic, degenerative aortic stenosis is overwhelmingly a disease of the elderly. As many as 300,000 individuals in the United States have symptomatic aortic stenosis (AS). Prior studies suggest that patients with asymptomatic but hemodynamically significant AS have a high risk of dying or developing symptoms. A Mayo Clinic study demonstrated that the 1, 2, and 5 year probabilities of remaining free from operation or death were 80%, 63%, and 25% respectively in a cohort of 622 patients (Pellikka et al. 2005). The development of symptoms portends a high risk of death (Carabello 2002). Surgical intervention with mechanical or tissue prosthetic valves has long been the gold standard for treatment. Improved operative techniques and more durable valvular prostheses have resulted in excellent functional status and patient survival. While operative mortality at experienced centers with careful patient selection is low, frequently patients with calcific AS have increased operative risk (OBrien et al. 2009). As such, a third to half of elderly patients with symptomatic AS are not candidates for operative intervention due to advanced age or severe co-morbidities (Bouma et al. 1999). Percutaneous aortic balloon valvuloplasty has not resulted in long-term relief, with early restenosis the rule.

Original languageEnglish (US)
Title of host publicationCardiac Valvular Medicine
PublisherSpringer-Verlag London Ltd
Pages103-110
Number of pages8
ISBN (Electronic)9781447141327
ISBN (Print)9781447141310
DOIs
StatePublished - Jan 1 2013

Fingerprint

Aortic Valve
Aortic Valve Stenosis
Balloon Valvuloplasty
Patient Selection
Prostheses and Implants
Morbidity
Survival
Mortality
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lloyd, M. A., & Rihal, C. S. (2013). Transcutaneous aortic valve implantation. In Cardiac Valvular Medicine (pp. 103-110). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-4471-4132-7_11

Transcutaneous aortic valve implantation. / Lloyd, Margaret A.; Rihal, Charanjit S.

Cardiac Valvular Medicine. Springer-Verlag London Ltd, 2013. p. 103-110.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lloyd, MA & Rihal, CS 2013, Transcutaneous aortic valve implantation. in Cardiac Valvular Medicine. Springer-Verlag London Ltd, pp. 103-110. https://doi.org/10.1007/978-1-4471-4132-7_11
Lloyd MA, Rihal CS. Transcutaneous aortic valve implantation. In Cardiac Valvular Medicine. Springer-Verlag London Ltd. 2013. p. 103-110 https://doi.org/10.1007/978-1-4471-4132-7_11
Lloyd, Margaret A. ; Rihal, Charanjit S. / Transcutaneous aortic valve implantation. Cardiac Valvular Medicine. Springer-Verlag London Ltd, 2013. pp. 103-110
@inbook{6e4e2c8b0ecd489a93c771d4e72f010a,
title = "Transcutaneous aortic valve implantation",
abstract = "Non-rheumatic, degenerative aortic stenosis is overwhelmingly a disease of the elderly. As many as 300,000 individuals in the United States have symptomatic aortic stenosis (AS). Prior studies suggest that patients with asymptomatic but hemodynamically significant AS have a high risk of dying or developing symptoms. A Mayo Clinic study demonstrated that the 1, 2, and 5 year probabilities of remaining free from operation or death were 80{\%}, 63{\%}, and 25{\%} respectively in a cohort of 622 patients (Pellikka et al. 2005). The development of symptoms portends a high risk of death (Carabello 2002). Surgical intervention with mechanical or tissue prosthetic valves has long been the gold standard for treatment. Improved operative techniques and more durable valvular prostheses have resulted in excellent functional status and patient survival. While operative mortality at experienced centers with careful patient selection is low, frequently patients with calcific AS have increased operative risk (OBrien et al. 2009). As such, a third to half of elderly patients with symptomatic AS are not candidates for operative intervention due to advanced age or severe co-morbidities (Bouma et al. 1999). Percutaneous aortic balloon valvuloplasty has not resulted in long-term relief, with early restenosis the rule.",
author = "Lloyd, {Margaret A.} and Rihal, {Charanjit S.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4471-4132-7_11",
language = "English (US)",
isbn = "9781447141310",
pages = "103--110",
booktitle = "Cardiac Valvular Medicine",
publisher = "Springer-Verlag London Ltd",

}

TY - CHAP

T1 - Transcutaneous aortic valve implantation

AU - Lloyd, Margaret A.

AU - Rihal, Charanjit S.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Non-rheumatic, degenerative aortic stenosis is overwhelmingly a disease of the elderly. As many as 300,000 individuals in the United States have symptomatic aortic stenosis (AS). Prior studies suggest that patients with asymptomatic but hemodynamically significant AS have a high risk of dying or developing symptoms. A Mayo Clinic study demonstrated that the 1, 2, and 5 year probabilities of remaining free from operation or death were 80%, 63%, and 25% respectively in a cohort of 622 patients (Pellikka et al. 2005). The development of symptoms portends a high risk of death (Carabello 2002). Surgical intervention with mechanical or tissue prosthetic valves has long been the gold standard for treatment. Improved operative techniques and more durable valvular prostheses have resulted in excellent functional status and patient survival. While operative mortality at experienced centers with careful patient selection is low, frequently patients with calcific AS have increased operative risk (OBrien et al. 2009). As such, a third to half of elderly patients with symptomatic AS are not candidates for operative intervention due to advanced age or severe co-morbidities (Bouma et al. 1999). Percutaneous aortic balloon valvuloplasty has not resulted in long-term relief, with early restenosis the rule.

AB - Non-rheumatic, degenerative aortic stenosis is overwhelmingly a disease of the elderly. As many as 300,000 individuals in the United States have symptomatic aortic stenosis (AS). Prior studies suggest that patients with asymptomatic but hemodynamically significant AS have a high risk of dying or developing symptoms. A Mayo Clinic study demonstrated that the 1, 2, and 5 year probabilities of remaining free from operation or death were 80%, 63%, and 25% respectively in a cohort of 622 patients (Pellikka et al. 2005). The development of symptoms portends a high risk of death (Carabello 2002). Surgical intervention with mechanical or tissue prosthetic valves has long been the gold standard for treatment. Improved operative techniques and more durable valvular prostheses have resulted in excellent functional status and patient survival. While operative mortality at experienced centers with careful patient selection is low, frequently patients with calcific AS have increased operative risk (OBrien et al. 2009). As such, a third to half of elderly patients with symptomatic AS are not candidates for operative intervention due to advanced age or severe co-morbidities (Bouma et al. 1999). Percutaneous aortic balloon valvuloplasty has not resulted in long-term relief, with early restenosis the rule.

UR - http://www.scopus.com/inward/record.url?scp=84898602042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898602042&partnerID=8YFLogxK

U2 - 10.1007/978-1-4471-4132-7_11

DO - 10.1007/978-1-4471-4132-7_11

M3 - Chapter

SN - 9781447141310

SP - 103

EP - 110

BT - Cardiac Valvular Medicine

PB - Springer-Verlag London Ltd

ER -